These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31030993)

  • 21. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
    Lokhorst HM; Plesner T; Laubach JP; Nahi H; Gimsing P; Hansson M; Minnema MC; Lassen U; Krejcik J; Palumbo A; van de Donk NW; Ahmadi T; Khan I; Uhlar CM; Wang J; Sasser AK; Losic N; Lisby S; Basse L; Brun N; Richardson PG
    N Engl J Med; 2015 Sep; 373(13):1207-19. PubMed ID: 26308596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety Analysis of Five Randomized Controlled Studies of Daratumumab in Patients With Multiple Myeloma.
    Al Hadidi S; Miller-Chism CN; Kamble R; Mims M
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):e579-e589. PubMed ID: 32409106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daratumumab Monotherapy in Heavily Pretreated Asian Patients With Relapsed and Refractory Multiple Myeloma: A Real-world Experience.
    Byun JM; Yoon SS; Koh Y; Kim I; Jo J; Park H; Lee JO; Lee J
    Anticancer Res; 2019 Sep; 39(9):5165-5170. PubMed ID: 31519629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 'Fast but not so Furious': Short observation time after subcutaneous Daratumumab administration is both a safe and cost-effective strategy.
    Davis JA; Youngberg H; Gaffney K; Duco M; Hashmi H
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e680-e684. PubMed ID: 35414476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Infusion of Daratumumab in Combination Therapies - Practical Information for The Outpatient Area].
    Scheid C; Munder M; Salwender H; Engelhardt M
    Dtsch Med Wochenschr; 2018 Aug; 143(16):1201-1206. PubMed ID: 29874684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-World Utilization and Safety of Daratumumab IV Rapid Infusions Administered in a Community Setting: A Retrospective Observational Study.
    Gordan L; Chang M; Lafeuille MH; Romdhani H; Paramasivam F; Maiese EM; McKay C
    Drugs Real World Outcomes; 2021 Jun; 8(2):187-195. PubMed ID: 33565004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and feasibility analysis of rapid daratumumab infusion in Chinese patients with multiple myeloma.
    Yin XX; Hu Y; Yang Y; Zhang X; Liu L; Cao X; Chen J; Xia Z; Wang Y
    Cancer Med; 2024 Jun; 13(11):e7347. PubMed ID: 38845476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
    Afifi S; Michael A; Lesokhin A
    Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Daratumumab in multiple myeloma.
    Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
    Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.
    Jullien M; Trudel S; Tessoulin B; Mahé B; Dubruille V; Blin N; Gastinne T; Bonnet A; Lok A; Lebourgeois A; Peterlin P; Garnier A; Chevalier P; Guillaume T; Thomaré P; Le Gouill S; Moreau P; Touzeau C
    Ann Hematol; 2019 Jun; 98(6):1435-1440. PubMed ID: 30874850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab.
    Nooka AK; Gleason C; Sargeant MO; Walker M; Watson M; Panjic EH; Lonial S
    J Oncol Pract; 2018 Jul; 14(7):414-422. PubMed ID: 29996069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study.
    Iida S; Suzuki K; Kusumoto S; Ri M; Tsukada N; Abe Y; Aoki M; Inagaki M
    Int J Hematol; 2017 Oct; 106(4):541-551. PubMed ID: 28643017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
    Mateos MV; Dimopoulos MA; Cavo M; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Kaplan P; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Chiu C; Wang J; Carson R; Crist W; Deraedt W; Nguyen H; Qi M; San-Miguel J;
    N Engl J Med; 2018 Feb; 378(6):518-528. PubMed ID: 29231133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice.
    Park SS; Eom HS; Kim JS; Koh Y; Choi CW; Lee JJ; Kim K; Suh C; Lee JH; Min CK;
    Jpn J Clin Oncol; 2019 Jan; 49(1):92-95. PubMed ID: 30476124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma.
    Bonello F; Rocchi S; Barilà G; Sandrone M; Talarico M; Zamagni E; Scaldaferri M; Vedovato S; Bertiond C; Pavan L; Bringhen S; Cattel F; Zambello R; Cavo M; Mina R
    Front Oncol; 2022; 12():851864. PubMed ID: 35359355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of bisphosphonate treatment among patients with multiple myeloma treated at oncology clinics across the USA: observations from real-world data.
    Kim C; Hernandez RK; Cyprien L; Liede A; Cheng PC
    Support Care Cancer; 2018 Aug; 26(8):2833-2841. PubMed ID: 29516168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
    Blair HA
    Drugs; 2017 Dec; 77(18):2013-2024. PubMed ID: 29127588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients.
    Lovas S; Varga G; Farkas P; Masszi T; Wohner N; Bereczki Á; Adamkovich N; Borbényi Z; Szomor Á; Alizadeh H; Szaleczky E; Wolf K; Schneider T; Plander M; Szendrei T; Csacsovszki O; Csukly Z; Rajnics P; Egyed M; Nagy Z; Rejtő L; Illés Á; Mikala G; Váróczy L
    Int J Hematol; 2019 Nov; 110(5):559-565. PubMed ID: 31392600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment.
    Clemens PL; Yan X; Lokhorst HM; Lonial S; Losic N; Khan I; Jansson R; Ahmadi T; Lantz K; Zhou H; Puchalski T; Xu XS
    Clin Pharmacokinet; 2017 Aug; 56(8):915-924. PubMed ID: 27896689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.